These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

214 related articles for article (PubMed ID: 28650573)

  • 21. A comparative analysis of postoperative pancreatic fistulas after surgery with and without hyperthermic intraperitoneal chemoperfusion.
    Downs-Canner S; Ding Y; Magge DR; Jones H; Ramalingam L; Zureikat A; Holtzman M; Ahrendt S; Pingpank J; Zeh HJ; Bartlett DL; Choudry HA
    Ann Surg Oncol; 2015 May; 22(5):1651-7. PubMed ID: 25348781
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Postoperative outcomes of laparoscopic vs open cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy for treatment of peritoneal surface malignancies.
    Passot G; Bakrin N; Isaac S; Decullier E; Gilly FN; Glehen O; Cotte E
    Eur J Surg Oncol; 2014 Aug; 40(8):957-62. PubMed ID: 24209429
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Recurrence and Survival Outcomes After Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Small Bowel Adenocarcinoma.
    Saxena A; Valle SJ; Liauw W; Morris DL
    Anticancer Res; 2017 Oct; 37(10):5737-5742. PubMed ID: 28982894
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cytoreductive Surgery and HIPEC in an Enhanced Recovery After Surgery Program: A Feasibility Study.
    Lu PW; Fields AC; Shabat G; Bleday R; Goldberg JE; Irani J; Stopfkuchen-Evans M; Melnitchouk N
    J Surg Res; 2020 Mar; 247():59-65. PubMed ID: 31767280
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Extreme cytoreductive surgery and hyperthermic intraperitoneal chemotherapy: Outcomes from a single tertiary center.
    Berger Y; Aycart S; Mandeli JP; Heskel M; Sarpel U; Labow DM
    Surg Oncol; 2015 Sep; 24(3):264-9. PubMed ID: 26143715
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Transient Exocrine Pancreatic Insufficiency: First Report of an Unrecognized Complication of Cytoreductive Surgery and HIPEC.
    Naffouje SA; Salti GI
    Anticancer Res; 2018 Apr; 38(4):2353-2358. PubMed ID: 29599360
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Predictors of Non-home Discharge after Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy.
    Kubi B; Gunn J; Fackche N; Cloyd JM; Abdel-Misih S; Grotz T; Leiting J; Fournier K; Lee AJ; Dineen S; Dessureault S; Veerapong J; Baumgartner JM; Clarke C; Mogal H; Patel SH; Dhar V; Lambert L; Hendrix RJ; Abbott DE; Pokrzywa C; Raoof M; Lee B; Maithel SK; Staley CA; Johnston FM; Wang NY; Greer JB
    J Surg Res; 2020 Nov; 255():475-485. PubMed ID: 32622162
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Iterative procedures combining cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for isolated peritoneal recurrence.
    Vaira M; Robella M; Mellano A; Sottile A; De Simone M
    Int J Hyperthermia; 2014 Dec; 30(8):565-9. PubMed ID: 25430988
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cirrhosis is not a contraindication to cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in highly selected patients.
    Weiss A; Ward EP; Baumgartner JM; Lowy AM; Kelly KJ
    World J Surg Oncol; 2018 Apr; 16(1):87. PubMed ID: 29699564
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy in Elderly Patients: Complete Cytoreduction Is Feasible and Crucial for Improved Survival Despite High Carcinomatosis Index.
    Naffouje SA; Salti GI
    Anticancer Res; 2018 Jan; 38(1):441-448. PubMed ID: 29277807
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Base Excess as a Predictor of Complications in Cytoreductive Surgery with Hyperthermic Intraperitoneal Chemotherapy.
    Eng OS; Dumitra S; O'Leary M; Wakabayashi M; Dellinger TH; Han ES; Lee SJ; Benjamin Paz I; Singh G; Lee B
    Ann Surg Oncol; 2017 Sep; 24(9):2707-2711. PubMed ID: 28560593
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Significance of diabetes on morbidity and mortality following cytoreductive surgery with hyperthermic intraperitoneal chemotherapy.
    Randle RW; Ahmed S; Levine EA; Fino NF; Swett KR; Stewart JH; Shen P; Votanopoulos KI
    J Surg Oncol; 2015 May; 111(6):740-5. PubMed ID: 25556634
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Repeated cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in peritoneal carcinomatosis from appendiceal cancer: analysis of survival outcomes.
    Sardi A; Jimenez WA; Nieroda C; Sittig M; Macdonald R; Gushchin V
    Eur J Surg Oncol; 2013 Nov; 39(11):1207-13. PubMed ID: 24007834
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Factors Associated with 60-Day Readmission Following Cytoreduction and Hyperthermic Intraperitoneal Chemotherapy.
    Kelly KJ; Cajas L; Baumgartner JM; Lowy AM
    Ann Surg Oncol; 2018 Jan; 25(1):91-97. PubMed ID: 29090402
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cytoreductive surgery with hyperthermic intraperitoneal chemotherapy for peritoneal malignancy: preliminary results of a multi-disciplinary teamwork model in Asia.
    Wang TY; Chen CY; Lu CH; Chen MC; Lee LW; Huang TH; Hsieh MC; Chen CJ; Yu CM; Chuang HC; Liao TT; Tseng CW; Huang WS
    Int J Hyperthermia; 2018 May; 34(3):328-335. PubMed ID: 28562119
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Anesthesia and Pain Management for Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Desmoplastic Small Round Cell Tumors in Children, Adolescents, and Young Adults.
    Anghelescu DL; Brown CL; Murphy AJ; Davidoff AM; Dickson PV; Glazer ES; Stiles ZE; Bishop MW; Douthitt L; Deneve JL
    Ann Surg Oncol; 2019 Jan; 26(1):131-138. PubMed ID: 30353396
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effect of a concomitant urologic procedure on outcomes following cytoreductive surgery with hyperthermic intraperitoneal chemotherapy.
    Lyon TD; Turner Ii RM; Nikonow TN; Wang L; Uy J; Ramalingam L; Holtzman MP; Pingpank JF; Bartlett DL; Davies BJ
    J Surg Oncol; 2016 Feb; 113(2):218-22. PubMed ID: 26775909
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Evaluation of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in a community setting: A cost-utility analysis of a hospital's initial experience and reflections on the health care system.
    Naffouje SA; O'Donoghue C; Salti GI
    J Surg Oncol; 2016 Apr; 113(5):544-7. PubMed ID: 26750613
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Indications for cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in elderly patients with peritoneal malignancy.
    Kitai T; Yamanaka K; Miyauchi Y; Kawashima M
    Int J Clin Oncol; 2017 Jun; 22(3):519-525. PubMed ID: 28054141
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Extensive surgical history prior to cytoreductive surgery and hyperthermic intraperitoneal chemotherapy is associated with poor survival outcomes in patients with peritoneal mucinous carcinomatosis of appendiceal origin.
    Milovanov V; Sardi A; Aydin N; Nieroda C; Sittig M; Nunez M; Gushchin V
    Eur J Surg Oncol; 2015 Jul; 41(7):881-5. PubMed ID: 25899982
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.